The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Quiz|Articles|May 22, 2026
OncLive Weekly News Quiz (5/22/2026): Test Your Knowledge on Updates in Bladder Cancer, NSCLC, and AML
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
- ”, no repetitive openers, each ending with a period).
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
A supplemental biologics license application for nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG is supported in part by findings from Cohort B of the phase 2/3 QUILT-3.032 trial (NCT03022825). What 12-month disease-free survival (DFS) rate was reported among patients with high-grade, papillary-only non–muscle-invasive bladder cancer (NMIBC)?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5